Received Dec 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
Nurse practitioner reported that a patient received a first dose of GARDASIL 9 in 10/2023 when the patient was 13 years old and did not get the second dose yet.; No additional AE; This spontaneous report was received from a nurse and refers to a 13-year-old patient of unknown gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On an unspecified date in October 2023, the patient received the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL9), (strength, dose, frequency, anatomical location, lot #, and expiration date were not reported) for prophylaxis. At the time of reporting, the patient did not get the second dose yet (Inappropriate schedule of product administration). No additional adverse event was reported. Lot # is being requested and will be submitted if received.